This article is more than 5 years old. Information may no longer be current.
Amgen, insurer agree on refund plan for CV events on evolocumab
Click Here to Manage Email Alerts
Amgen announced it signed a contract with Harvard Pilgrim, a health services company for the northeastern United States, to offer outcomes-based refunds for evolocumab, according to a press release.
According to the release, under the contract, the first of its kind, Harvard Pilgrim will receive a rebate for the cost of evolocumab (Repatha, Amgen) if an eligible individual has a MI or stroke while taking the medication.
This refund contract is based on data presented at a recent conference, in which reducing LDL by adding evolocumab to statin therapy lowered risk for CV events, according to the release.
“Amgen is committed to combating [CVD], one of the largest public health concerns in the world, and our value-based partnership with Harvard Pilgrim further demonstrates our confidence in the significant value that Repatha can bring to patients, payers and society,” Joshua J. Ofman, MD, MSHS, senior vice president of global value, access and policy at Amgen, said in the release. “Given the urgency to reduce LDL in patients at high risk [for CV] events, we value our relationship with leading health plans like Harvard Pilgrim who have worked with us to refine their utilization management criteria to accelerate access for their high-risk patients. We look forward to partnering with other payers to create similar outcomes-based contracts for Repatha.”
Disclosure: Ofman is an employee of Amgen.